NDA 021348 · Actelion
Zavesca
Miglustat · Oral · Glucosylceramide Synthase Inhibitor; Enzyme Stabilizer
NovelOrphanLast checked: Nov 20, 2026Latest source record: Dec 8, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jul 31, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
10 Phase 3, 2 recruiting
FAERS reports
1,085
967 serious, 311 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 25, 2023.
Miglustat is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option ( 1.1 ). 1.1 Type 1 Gaucher Disease Miglustat is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).
Mechanism: Type 1 Gaucher disease is caused by a functional deficiency of glucocerebrosidase, the enzyme that mediates the degradation of the glycosphingolipid glucosylceramide. Miglustat functions as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids. Miglustat helps reduce the rate of glycosphingolipid biosynthesis so that the amount of glycosphingolipid substrate is reduced to a level which allows the residual activity of the deficient glucocerebrosidase enzyme to be more...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZAVESCA · MIGLUSTAT 100MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Miglustat" as an intervention, any sponsor and status, largest first.
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT03729362 · 125 participants · Start Dec 4, 2018 · Primary completion Dec 15, 2020
Drug: Cipaglucosidase Alfa; Miglustat and 2 more · For: Pompe Disease (Late-onset)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Irvine, California · 73 sites in all
G D SearleIndustry
NCT00001993 · 120 participants
Drug: Butyldeoxynojirimycin; Zidovudine · For: HIV Infections
Sites: Miami, Florida; Chicago, Illinois; Indianapolis, Indiana · 6 sites in all
- A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)Pivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT04138277 · 119 participants · Start Dec 18, 2019 · Primary completion Dec 31, 2024
Drug: AT2221; ATB200 · For: Pompe Disease (Late-onset)
Sites: Little Rock, Arkansas; Irvine, California; Gainesville, Florida · 60 sites in all
G D SearleIndustry
NCT00000692 · 48 participants
Drug: Butyldeoxynojirimycin · For: HIV Infections
Sites: San Diego, California; Stanford, California; Miami, Florida · 6 sites in all
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01822028 · 42 participants · Start Mar 2013 · Primary completion Jun 2013
Drug: Treatment A; Treatment B · For: Diarrhea
Sites: Toronto, Canada
- Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher DiseasePivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00319046 · 42 participants · Start Feb 1, 2006 · Primary completion Jun 1, 2010
Drug: Miglustat · For: Gaucher Disease Type 1
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Pivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT04808505 · 36 participants (planned) · Start Jul 18, 2023 · Primary completion Jul 2027
Drug: Cipaglucosidase alfa; Miglustat · For: Glycogen Storage Disease Type II Infantile Onset
Sites: Gainesville, Florida; Atlanta, Georgia; Durham, North Carolina · 14 sites in all
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT00041535 · 30 participants · Start Jul 5, 2002
Drug: OGT 918 · For: Gaucher Disease
Sites: Bethesda, Maryland; London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea163
- death153
- seizure112
- niemann-pick disease97
- weight decreased97
- pneumonia86
- disease progression85
- tremor75
- condition aggravated74
- off label use73
- dysphagia66
- pyrexia61
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 13 |
| 2006 | 11 |
| 2007 | 9 |
| 2008 | 11 |
| 2009 | 6 |
| 2010 | 56 |
| 2011 | 56 |
| 2012 | 86 |
| 2013 | 70 |
| 2014 | 55 |
| 2015 | 89 |
| 2016 | 74 |
| 2017 | 81 |
| 2018 | 83 |
| 2019 | 52 |
| 2020 | 52 |
| 2021 | 115 |
| 2022 | 28 |
| 2023 | 33 |
| 2024 | 27 |
| 2025 | 40 |
| 2026 | 28 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zavesca (Miglustat)
2024 spending
$1.3M
Beneficiaries
n/a
56 claims
Per beneficiary
n/a
$188.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,367,726 |
| 2021 | $1,819,181 |
| 2022 | $2,046,912 |
| 2023 | $2,123,383 |
| 2024 | $1,343,537 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, et al. · Lancet Neurol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.
Mengel E, Patterson MC, Da Riol RM, et al. · J Inherit Metab Dis 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, et al. · J Neurol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of efavirenz in Niemann-Pick disease type C.
Gascón-Bayarri J, Rico I, Sánchez-Castañeda C, et al. · Neurotherapeutics 2025 · Clinical Trial, Phase II
- Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: A systematic review.
Mansouri V, Tavasoli AR, Khodarahmi M, et al. · Eur J Neurol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, et al. · J Patient Rep Outcomes 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.